Nursing Elites

1. When administering a Serotonin Antagonist, what is important to monitor for?

• A. Intake and output
• B. Mental status changes
• C. Respiratory rate
• D. Anorexia

Correct answer: B

Rationale: When administering a Serotonin Antagonist, monitoring mental status changes is crucial. Serotonin Antagonists can affect neurological function, potentially leading to alterations in mental status. It is essential to assess for any changes in behavior, mood, or cognition to ensure patient safety and prompt intervention if needed.

2. When educating a client who has a new prescription for Hydrochlorothiazide, which of the following statements should the nurse include?

• A. Take this medication in the morning.
• B. You may need to increase your intake of potassium.
• C. This medication may cause drowsiness.
• D. Avoid consuming grapefruit.

Correct answer: B

Rationale: The correct statement to include when educating a client with a new prescription for Hydrochlorothiazide is that they may need to increase their intake of potassium. Hydrochlorothiazide is a thiazide diuretic that can lead to potassium loss. Monitoring potassium levels and increasing potassium intake if necessary can help prevent complications associated with hypokalemia. Option A is not directly related to the medication's specific instructions. Option C is incorrect as Hydrochlorothiazide typically does not cause drowsiness. Option D is unrelated, as there is no interaction between Hydrochlorothiazide and grapefruit.

3. A client has a new prescription for Hydralazine. Which of the following side effects should the nurse instruct the client to monitor for and report?

• A. Orthostatic hypotension
• B. Increased heart rate
• C. Dark-colored urine
• D. Persistent cough

Correct answer: B

Rationale: Corrected Rationale: Hydralazine, a vasodilator, can cause reflex tachycardia, leading to an increased heart rate. This side effect should be reported to the healthcare provider to ensure appropriate management and monitoring of the client's condition. Choice A (Orthostatic hypotension) is incorrect as Hydralazine is more likely to cause reflex tachycardia than orthostatic hypotension. Choice C (Dark-colored urine) and Choice D (Persistent cough) are unrelated to the common side effects of Hydralazine and should not be the focus of monitoring for this medication.

4. A client with Graves' disease is being educated by a nurse about her prescribed medications. Which of the following statements by the client indicates an understanding of the use of Propranolol in the treatment of Graves' disease?

• A. Propranolol helps increase blood flow to my thyroid gland.
• B. Propranolol is used to prevent excess glucose in my blood.
• C. Propranolol will decrease my tremors and fast heartbeat.
• D. Propranolol promotes a decrease of thyroid hormone in my body.

Correct answer: C

Rationale: The correct answer is C. Propranolol is a beta-adrenergic antagonist that is commonly used in Graves' disease to decrease symptoms such as tremors and fast heart rate. Choice A is incorrect because Propranolol does not increase blood flow to the thyroid gland. Choice B is incorrect as Propranolol is not used to prevent excess glucose in the blood. Choice D is also incorrect as Propranolol does not directly decrease thyroid hormone levels in the body.

5. A client with chronic renal disease is receiving therapy with epoetin alfa. Which of the following laboratory results should the nurse review for an indication of a therapeutic effect of the medication?

• A. The leukocyte count
• B. The platelet count
• C. The hematocrit (Hct)
• D. The erythrocyte sedimentation rate (ESR)

Correct answer: C

Rationale: The correct answer is C: The hematocrit (Hct). Monitoring the hematocrit is essential to assess the therapeutic effect of epoetin alfa because this medication stimulates red blood cell production in clients with chronic renal disease. The leukocyte count (choice A) and platelet count (choice B) are not directly affected by epoetin alfa therapy. The erythrocyte sedimentation rate (ESR) (choice D) is a non-specific marker of inflammation and is not used to monitor the therapeutic effect of epoetin alfa.

Similar Questions